Kinnate Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Kinnate Biopharma

10/11/2022 22:35

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly
adjusted
loss of 70 cents​​ per share for the quarter ended in September.
The mean expectation of eight analysts for the quarter was for a
loss of 61 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kinnate Biopharma Inc's reported EPS for the quarter was a
loss
of 70 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.6%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kinnate Biopharma Inc shares had fallen by 29.5% this
quarter and lost 52.4% so far this year.
    * The company reported a quarterly loss of $30.74 million.
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $33.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:34 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.61          -0.70          Missed
 Jun. 30 2022      -0.64          -0.62          Beat
 Mar. 31 2022      -0.61          -0.61          Met
 Dec. 31 2021      -0.59          -0.60          Missed